Most Recent
A judge has ordered that class action firm Adero Law take down surveys from its website allegedly aimed at collecting registration data from group members in an underpayment class action against convenience store chain On The Run.
A Sydney law firm that brought a class action against Boston Scientific over allegedly defective pelvic mesh products has agreed to stay its case while a class action by Shine Lawyers moves ahead.
The lead applicant in a Maurice Blackburn-led class action against superannuation provider Colonial First State wants the Full Court to determine whether group members still have valid claims, after a judgment from the Victoria Supreme Court shut down a similar class action last year.
The Commonwealth says a landmark ruling in a class action that found it has a duty of care to protect Australian children from the effects of global warming is "incoherent" and distorts its ability to balance competing interests.
An appeals court has upheld a $100,000 sexual harassment judgment against a Sanitarium-owned company for designing, displaying and distributing a poster featuring a worker alongside the words "feel great - lubricate".
Noting that the legal costs of a dispute over whether she could represent federal minister Christian Porter in his defamation case were "substantial", Sue Chrysanthou SC has asked to see invoices before she agrees to a lump sum bill of $550,000.
ISignthis CEO John Karantzis has filed court proceedings against the ATO seeking to have $4.2 million lopped off his tax bill for the 2015 financial year.
Melbourne-based joint venture Shepparton Partners Collective has appealed a $1.2 million judgment which found it infringed software developer QAD's copyright by failing to pay a transfer fee to retain the licence after it acquired the iconic SPC Ardmona cannery in Victoria from Coca-Cola Amatil for $40 million.
Four witnesses who allegedly saw Ben Roberts-Smith kick a handcuffed man off a cliff in Afghanistan will give evidence next week in the war veteran’s defamation trial, which has been disrupted by COVID-19 restrictions in NSW.
Merck Sharp & Dohme has filed a lawsuit accusing rival drug company Bristol-Myers Squibb of misusing its market power by restricting access to a treatment program for stage IV melanoma patients.